Next Article in Journal
Mammary Development and Breast Cancer: A Wnt Perspective
Next Article in Special Issue
CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas
Previous Article in Journal
Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress
Previous Article in Special Issue
Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2016, 8(7), 64; doi:10.3390/cancers8070064

A Perspective of Immunotherapy for Prostate Cancer

1
Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy
2
Department of Urology, Sapienza University of Rome, Rome 00161, Italy
3
Department of Public Health hand Infectious Diseases, “Sapienza” University of Rome, Rome 00185, Italy
4
Medicine of Systems, Rheumatology, Allergology and Clinical Immunology, Translational Medicine of the University Tor Vergata, Rome 00133, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Vita Golubovskaya
Received: 28 April 2016 / Revised: 27 June 2016 / Accepted: 1 July 2016 / Published: 7 July 2016
(This article belongs to the Special Issue Cancer Immunotherapies)
View Full-Text   |   Download PDF [282 KB, uploaded 7 July 2016]

Abstract

In cancer patients, the immune system is often altered with an excess of inhibitory factors, such as immunosuppressive cytokines, produced by regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSC). The manipulation of the immune system has emerged as one of new promising therapies for cancer treatment, and also represents an attractive strategy to control prostate cancer (PCa). Therapeutic cancer vaccines and immune checkpoint inhibitors have been the most investigated in clinical trials. Many trials are ongoing to define the effects of immune therapy with established treatments: androgen deprivation therapy (ADT) and chemotherapy (CT) or radiotherapy (RT). This article discusses some of these approaches in the context of future treatments for PCa. View Full-Text
Keywords: prostate cancer; immune system; regulatory T cells; myeloid-derived suppressor cells; tumor associated macrophages; dendritic cells; immune therapy prostate cancer; immune system; regulatory T cells; myeloid-derived suppressor cells; tumor associated macrophages; dendritic cells; immune therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Silvestri, I.; Cattarino, S.; Giantulli, S.; Nazzari, C.; Collalti, G.; Sciarra, A. A Perspective of Immunotherapy for Prostate Cancer. Cancers 2016, 8, 64.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top